Background {#sec1_1}
==========

Pseudolymphoma is a benign nodular lesion that is histopathologically characterized by marked proliferation of nonneoplastic, polyclonal lymphocytes which form follicles with an active germinal center \[[@B1]\]. Pseudolymphoma can occur in various organs such as the skin \[[@B2]\], orbit \[[@B3]\], lung \[[@B4]\], and gastrointestinal tract \[[@B5]\], but it is rare in the liver. The preoperative diagnosis of hepatic pseudolymphoma is difficult because noninvasive radiological examinations such as ultrasonography (US), computed tomography (CT), and magnetic resonance imaging are usually equivocal. Recently, some reports have examined the use of fluorodeoxyglucose positron emission tomography (FDG-PET) in the diagnosis of hepatic pseudolymphoma \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12]\]. We herein report a case of hepatic pseudolymphoma with FDG uptake on PET and examine the literature.

Case Presentation {#sec1_2}
=================

A 69-year-old woman with chronic hepatitis B was admitted to our hospital for the further evaluation of a hepatic lesion that was identified by abdominal US during a health examination. She was asymptomatic and a physical examination revealed no remarkable abnormalities. A laboratory examination showed normal findings (including normal liver enzyme levels): white blood cell count 4,550/μL, hemoglobin 13.5 g/dL, aspartate aminotransferase 25 U/L, alanine aminotransferase 21 U/L, alkaline phosphatase 262 U/L, γ-glutamyltranspeptidase 16 U/L, and C-reactive protein 0.0 mg/dL. The patient was hepatitis B virus surface antigen-positive, but hepatitis C virus antibody-negative. The levels of the tumor markers carcinoembryonic antigen and carbohydrate antigen 19-9 (CA19-9) were elevated to 5.3 ng/mL (normal range: \<5 ng/mL) and 39.2 U/mL (normal range: \<37 U/mL), respectively. The α-fetoprotein and protein induced by vitamin K antagonist II (PIVKA-II) were within normal limits. Abdominal US showed a well-defined peripheral hypoechoic mass that was isoechoic and homogeneous on the inside (Fig. [1a](#F1){ref-type="fig"}). CT showed a poorly enhanced tumor of 13 mm in diameter in the 5th segment of the liver (Fig. [1b](#F1){ref-type="fig"}). FDG-PET showed a slight uptake by the hepatic tumor (maximum standard uptake value \[SUV max\] 3.4) (Fig. [1c](#F1){ref-type="fig"}). No other sites showed FDG uptake. Upper gastrointestinal endoscopy and colonoscopy did not reveal any pathological findings. Since these findings were suggestive of cholangiocellular carcinoma (CCC), the patient underwent laparotomy. No peritoneal dissemination was found during exploratory laparotomy. We therefore performed anterior segmentectomy of the liver. The resected specimen measured 13 × 12 mm in size and showed a well-defined, nonencapsulated and yellowish-white tumor (Fig. [2](#F2){ref-type="fig"}). Microscopy revealed that the lymph follicles varied in size and shape with germinal centers that were composed of small or large lymphoid cells and tangible body macrophages (Fig. [3a, b](#F3){ref-type="fig"}). An immunohistochemical examination revealed that the follicles were CD20-positive and bcl-2-negative (Fig. [3c, d](#F3){ref-type="fig"}). The interfollicular area was composed of CD3-positive small T cells (Fig. [3e](#F3){ref-type="fig"}). The lymphoid cells in follicles showed ordinary immunoreactivity, while the cells in the mantle zone were positive for CD5 and the cells in the germinal center were positive for CD10. A final diagnosis of hepatic pseudolymphoma was made on the basis of the histological and immunohistochemical findings.

The patient\'s postoperative course was uneventful, and he was discharged from the hospital on the 14th day after surgery. She remains alive without recurrence at 5 months after surgery.

Discussion {#sec1_3}
==========

Pseudolymphoma can occur in various organs such as the skin, orbit, lung, and gastrointestinal tract \[[@B2], [@B3], [@B4], [@B5]\]; it rarely occurs in the liver. Pseudolymphoma of the liver was first reported by Snover et al. \[[@B13]\] in 1981. Pseudolymphoma is also referred to as, "reactive lymphoid hyperplasia" or "nodular lymphoid lesion." Based on a review of the PubMed database from 1981 to 2016 using the keywords "pseudolymphoma," "reactive lymphoid hyperplasia," and "nodular lymphoid lesion," we found 71 cases, including our own case (Table [1](#T1){ref-type="table"}). The 71 patients included 7 (10%) males and 64 (90%) females. The female predilection of this disease was obvious. The average age of the patients was 59 years (range: 15--85). Fifty-five (77%) of these cases involved single tumors; 16 (23%) involved multiple tumors. The average tumor size (in greatest dimension) was 18 mm (range: 3--60 mm), and most of the tumors (63 cases: 89%) were ≤20 mm in size. The exact etiology of hepatic pseudolymphoma remains unclear. Associations between the development of hepatic pseudolymphoma and some diseases, such as autoimmune disease \[[@B1]\], malignant tumors \[[@B6]\], and chronic liver disease \[[@B14]\] have been suggested in previous reports. Among the 71 reported cases, 16 (23%) had autoimmune disease, 18 (25%) had malignant disease, and 21 (30%) had chronic liver disease. In our case, the patient was hepatitis B virus surface antigen-positive. However, we do not consider this to be a convincing finding. As a result of accumulation of the reported cases, a middle-aged female patient with hepatic tumor (≤20 mm) who has autoimmune disease, malignant tumors, or chronic liver disease should be suspected of having pseudolymphoma.

It is extremely difficult to preoperatively diagnose hepatic pseudolymphoma using US, CT, or magnetic resonance imaging. Hepatic pseudolymphoma has been misdiagnosed as hepatocellular carcinoma, CCC, and metastatic liver cancer. Recently, some reports have examined the use of FDG-PET in the diagnosis of hepatic pseudolymphoma. We found 9 cases in which FDG-PET was used to examine patients with hepatic pseudolymphoma, including our own (Table [2](#T2){ref-type="table"}) \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12]\]. Seven (78%) of 9 cases showed FDG uptake in the tumor, and the median SUV max was 4.3 (range: 3.4--7.2). In a previous report, the median SUV was 2.64 in hepatocellular carcinoma, 5.20 in CCC, and 4.38 in metastatic liver cancer \[[@B15]\]. Therefore, the accumulation of further case information will be needed to determine the utility of FDG-PET in differentiating between hepatic pseudolymphoma and other malignant hepatic tumors.

Percutaneous transhepatic needle biopsy is usually avoided in the preoperative period due to the risk of peritoneal dissemination. However, there are some reported cases in which hepatic pseudolymphoma was diagnosed by needle biopsy and followed up without surgical resection \[[@B14]\]. Therefore, needle biopsy may be performed in patients with suspected hepatic pseudolymphoma.

Conclusions {#sec1_4}
===========

Hepatic pseudolymphoma should be considered in the differential diagnosis of hepatic tumors, especially when a single small (≤20 mm) tumor is found in middle-aged female patients. FDG-PET and percutaneous transhepatic needle biopsy may be performed in patients with suspected hepatic pseudolymphoma.
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![**a** Abdominal US showed a well-defined peripheral hypoechoic mass that was isoechoic and homogeneous on the inside (arrow). **b** CT showed a poorly enhanced tumor of 13 mm in diameter in the 5th segment of the liver (arrow). **c** FDG-PET showed slight uptake by the hepatic tumor (SUV max 3.4) (arrow).](crg-0010-0826-g01){#F1}

![The resected specimen measured 13 × 12 mm in size and showed a well-defined, nonencapsulated, and yellowish-white tumor (arrow).](crg-0010-0826-g02){#F2}

![**a** Microscopically, the lymph follicles varied in size and shape and contained germinal centers. **b** The germinal centers of the lymphoid follicles were composed of small or large lymphoid cells and tangible body macrophages. **c** An immunohistochemical examination revealed that the follicles were CD20-positive. **d** An immunohistochemical examination revealed that the follicles were bcl-2-negative. **e** An immunohistochemical examination revealed that the interfollicular area was composed of CD3-positive small T cells.](crg-0010-0826-g03){#F3}

###### 

Clinical presentation of reported cases of hepatic pseudolymphoma (total *n* = 71)

  ------------------------------- -------------------
  Age, years                      59 (range 15--85)
  Gender                          
   Male                           7 (10%)
   Female                         64 (90%)
  Associated autoimmune disease   16 (23%)
   Sjögren syndrome               04
   Autoimmune thyroiditis         04
   Autoimmune hepatitis           02
   Takayasu disease               02
   Antiphospholipid syndrome      01
   CREST syndrome                 01
   Immunodeficiency               02
  Associated cancer               18 (25%)
   Colon cancer                   05
   Gastric cancer                 04
   Renal cell cancer              03
   Ovarian cancer                 01
   Bile duct cancer               01
   Pancreatic cancer              01
   Cervical cancer                01
   Breast cancer                  01
   HCC                            01
  Associated liver disease        21 (30%)
   PBC                            11
   Chronic viral hepatitis B      05
   Chronic viral hepatitis C      02
   Steatohepatitis                03
  Preoperative diagnosis          54 (described)
   HCC                            29
   Metastatic tumor               13
   CCC                            05
   Pseudolymphoma                 03
   Others                         04
  Tumor number                    
   Solitary                       55
   Multiple                       16
  Tumor size, mm                  18 (range 3--60)
  Treatment                       64 (described)
   Resection                      54
   Biopsy                         07
   Others                         03
  ------------------------------- -------------------

HCC, hepatocellular carcinoma; PBC, primary biliary cirrhosis; CCC, cholangiocellular carcinoma.

###### 

Reported cases of hepatic pseudolymphoma examined by FDG-PET

  Case        First author \[Ref.\]   Year   Age, years   Sex   Preoperative diagnosis        Tumor, *n*   Tumor size, mm   FDG uptake        Treatment   Associated disease
  ----------- ----------------------- ------ ------------ ----- ----------------------------- ------------ ---------------- ----------------- ----------- ----------------------
  1           Lin \[[@B6]\]           2008   44           f     Metastasis tumor              1            15               (+) SUV max 4.3   Resection   Colon cancer
  2           Marchetti \[[@B7]\]     2011   58           f     Metastasis tumor              1            12               (+) SUV max 7.2   Resection   Ovarian cancer
  3           Hayashi \[[@B8]\]       2011   56           f     Metastasis tumor or HCC       1            10               (+) SUV max 3.6   TAE,        
  resection   None                                                                                                                                        
  4           Lv \[[@B9]\]            2015   50           f     HCC                           1            10               (--)              Resection   None
  5           Lv \[[@B9]\]            2015   62           f     HCC                           1            9                (--)              Resection   None
  6           Calvo \[[@B10]\]        2015   70           f     ND                            1            18               (+)               Resection   PBC
  7           Kwon \[[@B11]\]         2015   41           f     Hepatic adenoma               1            25               (+)               Resection   Autoimmune hepatitis
  8           Taguchi \[[@B12]\]      2015   78           f     Malignant hepatic tumor       4            13               (+) SUV max 4.6   Resection   Tremors
  9           Our case                2017   69           f     Cholangiocellular carcinoma   1            13               (+) SUV max 3.4   Resection   Hepatitis B

FDG-PET, fluorodeoxyglucose positron emission tomography; f, female; SUV max, maximum standard uptake value; ND, not described; HCC, hepatocellular carcinoma; TAE, transcatheter arterial embolization; PBC, primary biliary cirrhosis.
